Evaluation of a Speech-to-noise Feedback Device for Treatment of Hypophonia in Parkinson's Disease
NCT ID: NCT03648749
Last Updated: 2019-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
25 participants
INTERVENTIONAL
2019-03-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Speech-in-Noise Treatments for Hypophonia in Parkinson's Disease
NCT04323085
An RCT of a Telemedicine Intervention for Hypokinetic Dysarthria in PD
NCT04617496
Voice Treatment for Parkinson's Disease
NCT03700684
Improve Speech Using an In-the-ear Device in Parkinson's Disease
NCT00488657
Efficacy of Voice Treatment for Parkinson's Disease
NCT00123084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Speech-to-noise feedback
A target speech-to-noise level is specified and feedback about achievement of the target level is provided
Speech-to-noise feedback
A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Speech-to-noise feedback
A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* stabilized on antiparkinsonian medication.
* good general health.
* pass a 40 decibel hearing screening.
* proficient enough in English to participate in speech testing.
Exclusion Criteria
* history of speech impairment that is unrelated to Parkinson's disease.
45 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Western Ontario, Canada
OTHER
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott Adams, PhD
Role: PRINCIPAL_INVESTIGATOR
Western University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LawsonHRI
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Mandar Jog, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
111861
Identifier Type: OTHER
Identifier Source: secondary_id
LawsonHRI5264
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.